Tumors and the immune response interact in various ways. Tumors try to suppress the immune response in an effort to promote their growth and survival. The anti-tumor immune response, on the other hand, identifies tumor cells and kills them. Both tumors and the immune response elicit various mechanisms to combat the actions of the other.
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-re...
The majority of patients with advanced NSCLC do not respond to monotherapy with PD-1 axis inhibition, and more robust predictive biomarkers are needed. In this study, we assessed tumor sampl...
Background: Growing evidence supports the critical role of preexisting immune response in triple negative breast cancer (TNBC). However, there are limitations with current evaluation approac...
The GeoMx Digital Spatial Profiling technology enables high-plex RNA and protein profiling of any region within any tissue type. This workshop will highlight the latest developments toward e...
DATE: May 8, 2020 TIME: 8:00am PT, 11:00am ET Microsatellite instability (MSI) is the condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). Studies indic...
Date: April 29, 2020 Time: 8:00AM PDT, 11:00AM EDT Single cell genomics and other next generation sequencing applications depend strongly on adequate upstream sample preparation. Results can...
DATE: April 14, 2020 TIME: 9:00am PDT, 12:00pm EDT Besides being Gibco Cell Culture Heroes, what do Vivek, Sandra, Daisy, Ameet and Kristine all have in common? They are all stuck at home fo...
DATE: March 31, 2020 TIME: 7:00am PT, 10:00am PT Please join us for this webinar, during which we will present and discuss the promotion of NK cell-driven tumor immunity. In addition, we wil...
Episodic memories are essential for human cognition, but the underlying neural mechanisms remain poorly understood. We utilize the opportunity to record in-vivo from human single neurons sim...
Whether you are performing killing assays, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conc...
Digital spatial profiling (DSP) on the NanoString GeoMx platform enables high plex molecular profiling of clinical tissue samples. This new profiling strategy enables deep insights into the...
Recent advances in DNA sequencing and omics-based capabilities are revealing incredible therapeutic opportunities and quickly transforming drug discovery. Molecularly targeted drugs aim to e...
“The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo...
DATE: December 17, 2019TIME: 8:00am PSTMass cytometry instruments simultaneously measure >50 cellular features, with a typical experiment including millions of cells. Dysregulated...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-re...
The majority of patients with advanced NSCLC do not respond to monotherapy with PD-1 axis inhibition, and more robust predictive biomarkers are needed. In this study, we assessed tumor sampl...
Background: Growing evidence supports the critical role of preexisting immune response in triple negative breast cancer (TNBC). However, there are limitations with current evaluation approac...
The GeoMx Digital Spatial Profiling technology enables high-plex RNA and protein profiling of any region within any tissue type. This workshop will highlight the latest developments toward e...
DATE: May 8, 2020 TIME: 8:00am PT, 11:00am ET Microsatellite instability (MSI) is the condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). Studies indic...
Date: April 29, 2020 Time: 8:00AM PDT, 11:00AM EDT Single cell genomics and other next generation sequencing applications depend strongly on adequate upstream sample preparation. Results can...
DATE: April 14, 2020 TIME: 9:00am PDT, 12:00pm EDT Besides being Gibco Cell Culture Heroes, what do Vivek, Sandra, Daisy, Ameet and Kristine all have in common? They are all stuck at home fo...
DATE: March 31, 2020 TIME: 7:00am PT, 10:00am PT Please join us for this webinar, during which we will present and discuss the promotion of NK cell-driven tumor immunity. In addition, we wil...
Episodic memories are essential for human cognition, but the underlying neural mechanisms remain poorly understood. We utilize the opportunity to record in-vivo from human single neurons sim...
Whether you are performing killing assays, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conc...
Digital spatial profiling (DSP) on the NanoString GeoMx platform enables high plex molecular profiling of clinical tissue samples. This new profiling strategy enables deep insights into the...
Recent advances in DNA sequencing and omics-based capabilities are revealing incredible therapeutic opportunities and quickly transforming drug discovery. Molecularly targeted drugs aim to e...
“The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo...
DATE: December 17, 2019TIME: 8:00am PSTMass cytometry instruments simultaneously measure >50 cellular features, with a typical experiment including millions of cells. Dysregulated...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
